Floyd, James SSitlani, Colleen MAvery, Christy LNoordam, RaymondLi, XiaohuiSmith, Albert VGogarten, Stephanie MLi, JinBroer, LindaEvans, Daniel STrompet, StellaBrody, Jennifer AStewart, James DEicher, John DSeyerle, Amanda ARoach, JeffreyLange, Leslie ALin, Henry JKors, Jan AHarris, Tamara BLi-Gao, RuifangSattar, NaveedCummings, Steven RWiggins, Kerri LNapier, Melanie DStürmer, TilBis, Joshua CKerr, Kathleen FUitterlinden, André GTaylor, Kent DStott, David Jde Mutsert, RenéeLauner, Lenore JBusch, EvanMéndez-Giráldez, RaúlSotoodehnia, NonaSoliman, Elsayed ZLi, YunDuan, QingRosendaal, Frits RSlagboom, P ElineWilhelmsen, Kirk CReiner, Alexander PChen, Yii-Der IHeckbert, Susan RKaplan, Robert CRice, Kenneth MJukema, J WouterJohnson, Andrew DLiu, YongmeiMook-Kanamori, Dennis OGudnason, VilmundurWilson, James GRotter, Jerome ILaurie, Cathy CPsaty, Bruce MWhitsel, Eric ACupples, L AdrienneStricker, Bruno H2017-07-242016Floyd, J. S., C. M. Sitlani, C. L. Avery, R. Noordam, X. Li, A. V. Smith, S. M. Gogarten, et al. 2016. “Large-scale pharmacogenomic study of sulfonylureas and the QT, JT, and QRS intervals: CHARGE Pharmacogenomics Working Group.” The pharmacogenomics journal :10.1038/tpj.2016.90. doi:10.1038/tpj.2016.90. http://dx.doi.org/10.1038/tpj.2016.90.http://nrs.harvard.edu/urn-3:HUL.InstRepos:33490964Sulfonylureas, a commonly-used class of medication used to treat type 2 diabetes, have been associated with an increased risk of cardiovascular disease. Their effects on QT interval duration and related electrocardiographic phenotypes are potential mechanisms for this adverse effect. In eleven ethnically diverse cohorts that included 71 857 European, African American, and Hispanic/Latino ancestry individuals with repeated measures of medication use and electrocardiogram (ECG) measurements, we conducted a pharmacogenomic genome-wide association study of sulfonylurea use and three ECG phenotypes: QT, JT, and QRS intervals. In ancestry-specific meta-analyses, 8 novel pharmacogenomic loci met the threshold for genome-wide significance (P < 5 x 10−8), and a pharmacokinetic variant in CYP2C9 (rs1057910) that has been associated with sulfonylurea-related treatment effects and other adverse drug reactions in previous studies was replicated. Additional research is needed to replicate the novel findings and to understand their biological basis.en-USJournal Article2017-07-2410.1038/tpj.2016.90